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Systolic time ratio measured by impedance
cardiography accurately screens left
ventricular diastolic dysfunction in patients
with arterial hypertension
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Abstract
Background: The use of impedance cardiography (ICG) may play a role in the assessment of cardiac effects of
hypertension (HT), especially its hemodynamic features. Hypertensive heart disease involves structural changes and
alterations in left ventricular geometry that end up causing systolic and/or diastolic dysfunction. The IMPEDDANS
study aims to assess the usefulness of ICG for the screening of left ventricular diastolic dysfunction (LVDD) in
patients with HT.
Methods: Patients with HT were assessed by echocardiography and ICG. Receiver-operating characteristic curve
and the area under the curve were used to assess the discriminative ability of the parameters obtained by ICG to
identify LVDD, as diagnosed by echocardiography.
Results: ICG derived pre-ejection period (PEP), left ventricle ejection time (LVET), systolic time ratio (STR) and D
wave were associated (p < 0.001) with LVDD diagnosis, with good discriminative ability: PEP (AUC 0.81; 95% CI 0.74–
0.89), LVET (AUC 0.82; 95% CI 0.75–0.88), STR (AUC 0.97; 95% CI 0.94–1.00) and presence of D wave (AUC = 0.87; 95%
CI 0.82–0.93). STR ≥ 0.30 outperformed the other parameters (sensitivity of 98.0%, specificity of 90.2%, positive
predictive value of 95.2%, and negative predictive value of 96.1%).
Conclusion: The ICG derived value of STR allows the accurate screening of LVDD in patients with HT. It might as
well be used for follow up assessment.
Trial registration: The study protocol was retrospectively registered as IMPEDDANS on ClinicalTrials.gov (ID:
NCT03209141) on July 6, 2017.
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Background
Arterial hypertension (HT) causes high morbidity and
mortality [1]. The progression of hypertensive heart
disease involves myocardial fibrosis and changes in left
ventricular geometry that precedes functional changes [2].
Diastolic dysfunction is part of this continuum, and
despite the growing recognition of its importance, it is
generally undervalued because of the difficulty in its diag-
nosis and the absence of effective therapies [3]. Currently,
the asymptomatic cardiac damage repercussion of HT is
mainly evaluated by electrocardiography and by echocar-
diography [4]. Cardiac magnetic resonance imaging (MRI)
is an alternative diagnostic examination but should only be
considered for assessment of left ventricle (LV) size and
mass when echocardiography is not feasible (or, in less fre-
quent situations, when imaging of delayed enhancement
could have therapeutic implications). Impedance cardiog-
raphy (ICG) is a non-invasive, non-operator dependent,
low-cost complementary diagnostic tool that easily allows
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characterizing a hypertensive patient’s hemodynamic
phenotypic profile and optimizing the antihypertensive
therapy [5, 6]. It analyses and registers hemodynamic
changes through the measurement of electrical resistance
changes in the thorax and translating them graphically as
impedance and electrocardiogram waveforms [5, 7, 8]. This
technique has evolved in recent years, making it an attract-
ive and economical alternative approach. However, it is
recognized that well-designed clinical trials are lacking in
well-defined populations, in order to justify its widespread
use in clinical practice [9–12]. Some other more specific
procedures are reserved only for diagnosis of myocardial is-
chaemia in hypertensive patients with LV hypertrophy [4].
Therefore it is important to have alternative tests for the
initial assessment of diastolic function in hypertensive
patients.
In diastolic dysfunction, there is a relative shift in LV
filling to the final part of the diastole with a greater de-
pendence on atrial contraction. These changes can be
detected by Doppler echocardiography and by ICG [2].
The phase of rapid passive ventricular filling at the onset
of diastole produces the E wave and the atrial contraction
produces the A wave. The E and the A waves on the Dop-
pler sonography correspond to the O and A waves in ICG,
respectively [13, 14]. Normally, the E wave in Doppler is
higher than the A wave, whereas in diastolic dysfunction,
the E wave is prolonged and becomes smaller than the A
wave. ICG can detect diastolic dysfunction by revealing a
delayed O wave (called a D wave) when contractility is
normal, [14] whereas diastolic dysfunction produces a sig-
nificant increase in the amplitude and duration of A wave
(Fig. 1) [5]. A D wave with an amplitude above the dZ/dt
baseline greater than one third of the amplitude of the
corresponding E wave is considered abnormal [15].
The pre-ejection period (PEP), corresponding to the
interval between the depolarization onset (Q-wave) and
aortic valve opening that includes the excitation-
contraction coupling and isovolumetric contraction of
the LV, decreases with increasing LV pressure at the end
of diastole, the main physiological consequence of dia-
stolic dysfunction [16–18]. On the other hand, the left
ventricular ejection time (LVET), measured as the inter-
val between the opening of the aortic valve and its clos-
ure, increases in patients with diastolic dysfunction. It
has been reported that a marked increase in LVET oc-
curs in patients with isolated diastolic dysfunction and
that this increase correlates with the severity of diastolic
dysfunction [19]. Thus, in diastolic dysfunction, the sys-
tolic time ratio (STR) is expected to decrease (STR =
PEP / LVET).
The thoracic fluid content (TFC) reflects the total
volume of fluid (intravascular and extravascular) within
the thoracic cavity, being inversely related to patient
transthoracic electrical bioimpedance. It is therefore a
reliable index of fluid overload in ambulatory patients.
This parameter increases with the evolution of diastolic
dysfunction being a sign of severity and has recently
been proposed for monitoring diastolic heart failure pa-
tients [20, 21].
The purpose of IMPEDDANS study is to assess the
usefulness of ICG in the screening of LV diastolic dys-
function (LVDD) in patients with HT.
Fig. 1 ICG waves in diastolic dysfunction (adapted from Bour et al. [5])
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Methods
This is a validation study of a diagnostic method (ICG)
used for a new purpose (diagnosis of LVDD) comparing it
with the clinical standard (echocardiography), the method
currently used for this effect in usual clinical practice.
Patients of either gender, aged 18–75 years, diagnosed
with grade 2 or 3 HT (systolic blood pressure [BP] ≥
160 mmHg and/or diastolic BP ≥ 100 mmHg) and/or
with resistant hypertension (according the definition of
ESH/ESC guidelines), [4] followed up in ambulatory
clinic of an Internal Medicine Department of a tertiary
referral hospital were eligible for recruitment.
Patients were excluded in the presence of: pregnancy,
height less than 120 cm or more than 230 cm, weight less
than 30 kg or greater than 155 kg, heart failure II-IV
NYHA, [22] heart rate (HR) less than 50 bpm or greater
than 110 bpm, atrial fibrillation or flutter, more than three
premature ventricular contractions per hour, complete left
bundle branch or atrioventricular block, pacemaker, se-
vere valvulopathy, constrictive pericarditis, hypertrophic
and restrictive cardiomyopathy, ischaemic heart disease
and/or segmental kinetics anomalies assessed by echocar-
diography, left ejection fraction <50%, or poor echocardio-
graphic window.
Recruitment began in January 2015 and was finished
in July 2017.
Sample size was estimated to test a hypothesized posi-
tive predictive value of 70 ± 5% of the ICG parameters
with 95% confidence. Since the prevalence of LVDD in
patients with HT is estimated, in most studies, [2, 23,
24] to be approximately 50%, to reach an effective sam-
ple of 77 patients with LVDD, the sample to be recruited
was doubled to 154 hypertensive patients.
Considering that it would not be ethically acceptable
to perform right heart catheterization of patients with
grade 2 or 3 HT, we chose to design a concordance
study between ICG and echocardiography, which is the
clinical standard for the diagnosis of LVDD and
characterization of hypertensive cardiomyopathy.
Participants were invited to be systematically assessed by
ICG and echocardiography, within a maximum interval of
8 days. To ensure that both tests were performed under
similar conditions, evaluations matching variations greater
than 10% in BP or variations more than 5% in HR were not
considered. These patients were asked to repeat at least one
of the exams. If the variations persisted, they were excluded.
Demographic and clinical baseline data were collected
from the patients’ medical records. Outpatient HT clinic
protocol requires clinical evaluation, blood chemistry
tests, electrocardiogram (EKG) and, eventually, 24 h am-
bulatory blood pressure monitoring (AMBP). Data re-
garding the comorbidities and medication were
collected. Body mass index was calculated as weight (kg)
divided by height (m) squared.
ICG was carried out by an experienced cardiopneumol-
ogy technician with Niccomo – Non-Invasive Continuous
Cardiac Output Monitor (Medis, GmbH, Ilmenau,
Germany) according the approved department protocol.
According to this, patients had to present with 6 h of fast-
ing but took their usual antihypertensive drugs. It was car-
ried out in supine position during 20 min (continuous
recording) and 70° orthostatism with the help of the tilting
table (10 min in continuous recording). The test was inter-
rupted if there was syncope or pre-syncope; dizziness,
nausea and malaise associated with poorly tolerated
hypotension and/or bradycardia; pain/precordial discom-
fort; EKG ST segment changes; systolic BP > 210 mmHg.
Table 1 presents the evaluated parameters.
Transthoracic echocardiography was performed in
Vivid E9 and S5 devices (GE Healthcare, Chicago, Illi-
nois, USA), always by the same three experienced cardi-
ologists. To ensure uniformity of evaluation and correct
evaluation, all exams were reviewed by one of the other
cardiologists. In order to diagnose and classify diastolic
dysfunction, the left atrium volume index, the velocities
E, A, septal e’, lateral e’, deceleration time (DT), isovolu-
metric relaxation time (IRVT), atrial reverse velocity
(Ar) and E/A ratio variation with Valsalva manoeuvre
were recorded (whenever the patient cooperated and if
the images obtained had the necessary quality for ana-
lysis) as recommended by 2009 guidelines. We consid-
ered that patients had LVDD when present septal e’ < 8,
lateral e’ < 10 and left atrial volume equal or greater than
34 mL/m2 (Fig. 2) [25].
The estimated efficacy and effectivity measures are the
positive predictive value (PPV), negative predictive value
(NPV), sensitivity and specificity of the presence of the
D wave and the values of PEP, LVET, STR, and TFC ob-
tained by ICG to detect LVDD.
Categorical variables were described with frequencies
and percentages. After evaluating the normal distribu-
tions of the continuous variables by the Kolmogorov-
Smirnov test and histograms analysis, the variables that
presented normal distribution were described with mean
and standard deviation, and the variables without nor-
mal distribution were described with median and inter-
quartile range (25th percentile, P25 - 75th percentile,
P75) or amplitude (minimum - maximum).
To compare the ICG parameters between patients
with and without LVDD, Mann-Whitney test was used.
Cut-off points were determined for ICG parameters
(PEP, LVET and STR) as predictors of occurrence of
LVDD. Using the receiver-operating characteristic
(ROC) curve cut-off points were determined regarding
the diagnosis of LVDD capacity for screening purposes,
thus high sensitivity was considered (>90%). The area
under the curve (AUC) was estimated and 95% confi-
dence intervals calculated using the binomial exact
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Table 1 Parameters assessed in impedance cardiography
Parameter Definition Formula
Heart rate Number of heart beats per minute (bpm) RR interval measurement on the ECG and
extrapolation for bpm
Mean blood pressure (MAP) Average pressure exerted by the blood on the arterial walls Automatic (oscillometric method) = MAP is
measured directly and SBP and DBP are
derived
Cardiac output (CO) Amount of blood ejected from the left ventricle / minute CO = Stroke volume x Heart rate
Cardiac index (CI) Standard CO for the body surface area (BSA) CI = CO / BSA
Stroke volume (SV) Amount of blood ejected from the left ventricle / heart
beat
SV = VEPT x LVET x VI
(Z MARC Algorithm)
Stroke volume index (SVI) Standard SV for the BSA SVI = SV / BSA
Vascular systemic resistance (VSR) Resistance to circulating blood in the arterial system VSR = 80 x ((MAP-CVP)/CO)
Vascular systemic resistance index (VSRI) Standard resistance to circulating blood in the arterial
system for the BSA
VSRI = 80 x ((MAP-CVP)/CI)
Acceleration index (AI) Initial acceleration of blood in the aorta that occurs within
the first 10–20 milliseconds after opening of the aortic
valve
AI = (d2Z/dt2Max)/TFI
Velocity index (VI) Aorta blood velocity peak VI = (dZ/dtMax)/TFI
Thoracic fluid (TF) Electrical conductivity of the thoracic cavity (determined by
intravascular, interalveolar and interstitial fluids)
TF = 1/TFI
Left heart work (LHW) Indicator of the amount of work the left ventricle exerts to
pump blood every minute
LHW = (MAP – PAOP) x CO
Left heart work index (LHWI) Standard LHW for the BSA LHW = (MAP – PAOP) x CI
Systolic time ratio (STR) Ratio of electrical and mechanical systole STR = PEP / LVET
Pre-ejection period (PEP) Time interval from the beginning of the electrical
stimulation of the ventricles to the beginning of the
opening of the aortic valve (electric systole)
Time interval between the start of wave Q on
the ECG and point B on wave dZ / dt
(opening of the aortic valve)
Left ventricular ejection time (LVET) Time interval from opening to closing of the aortic valve
(mechanical systole)
Time interval from point B to point X on
wave dZ / dt
CVP Central venous pressure (pressure in the thoracic and right atrial vein - 6 mmHg is considered by default), dZ / dtMax Maximum of the first derivative of ΔZ,
d2Z / dt2Max Maximum of the second derivative of ΔZ, PAOP Pulmonary artery occlusion pressure (considered by default as 10 mmHg), TFI Thoracic fluid index
(baseline thoracic impedance, Z0), VEPT Volume of electrically participating tissue (conductive volume for chest size affected by weight, height and sex)
Fig. 2 Practical approach to grade diastolic dysfunction (adapted from Nagueh et al. [25])
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confidence interval method [26]. Dichotomized ICG pa-
rameters by the obtained cut-off points, were used to es-
timate the test performance measures (sensitivity,
specificity, positive and negative predictive values as well
as false positive and negative rates). The level of signifi-
cance α = 0.05 was considered. Data were analysed with
SPSS 22.0 (SPSS for Windows, Rel. 22.0.1. 2013. SPSS
Inc., Chicago, Il, EUA) and MedCalc Statistical Software
version 16.4.3 (MedCalc Software bvba, Ostend,
Belgium; https://www.medcalc.org; 2016).
The study protocol was approved by the hospital’s Eth-
ics Committee (approval number 166/2014). Informed
consent was obtained from each patient.
The study protocol is registered as IMPEDDANS on
ClinicalTrials.gov (ID: NCT03209141).
Results
IMPEDDANS study recruited 167 patients. Ten patients
were excluded: three had syncope during ICG, three
gave up and did not perform the tests, three had a
significant dysrhythmia and one was diagnosed with
atrial septal defect. From the 157 hypertensive patients
included, 102 (65%) had LVDD (diagnosed by echocar-
diogram). Table 2 shows the main demographic, clinical
and hemodynamic characteristics of the patients.
The patients with LVDD diagnosis had significantly
lower PEP and STR and higher LVET and TFC than the
patients without LVDD (Table 3 and Fig. 3). The D wave
was more frequently identified among patients with
LVDD (Table 3) and its presence was also associated
with LVDD diagnosis.
The diagnostic performance was estimated for those
ICG parameters significantly associated with the diag-
nosis of LVDD. The AUC estimated for PEP was 0.81
(95% CI 0.74–0.87; p < 0.001), for LVET the AUC was
0.82 (95% CI 0.75–0.87; p < 0.001), the AUC was 0.97
(95% CI 0.93–0.99; p < 0.001) for STR and for the
presence D wave the AUC was 0.88 (95% CI 0.82–
0.93; p < 0.001) (Fig. 4). From the analysis of the ROC
curves, were defined the following cut-off points for







Males, n (%) 88 (56.1) 28 (50.9) 60 (58.8)
Age, mean (SD) 63 (10) 58 (11) 65 (9)
Caucasian, n (%) 142 (90.4) 48 (87.3) 94 (92.1)
HT duration (months), mean (SD) 120 (104) 47 (53) 160 (104)
Resistant HT, n (%) 117 (74.5) 41 (74.5) 76 (74.5)
Obesity, n (%) 82 (52.2) 31 (56.4) 51 (50.0)
Diabetes Mellitus, n (%) 81 (51.6) 28 (52.8) 53 (51.9)
Dyslipidaemia, n (%) 133 (84.7) 47 (85.5) 86 (84.3)
CKD, n (%) 49 (31.2) 12 (21.8) 37 (36.3)
Stroke, n (%) 36 (22.9) 13 (23.6) 23 (22.5)
COPD, n (%) 20 (12.7) 5 (9.1) 15 (14.7)
OSA, n (%) 31 (19.7) 8 (14.5) 23 (22.5)
Smoker, n (%) 34 (21.7) 6 (10.9) 28 (27.5)
Alcoholic, n (%) 16 (10.8) 6 (10.9) 10 (98.0)
N° of AHT drugs, median (min-max) 4 (1–7) 4 (1–7) 4 (1–6)
SBP (mmHg), median (P25-P75) 131 (122–142) 124 (118–135) 133 (126–144)
DBP (mmHg), median (P25-P75) 78 (72–84) 78 (73–84) 77 (72–84)
MBP (mmHg), median (P25-P75) 91 (85–99) 91 (84–96) 92 (85–101)
HR (bpm), median (P25-P75) 63 (57–70) 66 (60–74) 62 (56–69)
SVI (ml/m2), median (P25-P75) 43 (35–51) 37 (31–45) 46 (39–54)
CI (l/min/m2), median (P25-P75) 2.7 (2.4–3.1) 2.6 (2.3–2.8) 2.8 (2.5–2.4)
LCWI (kg.m/m2), median (P25-P75) 3.3 (2.7–3.8) 3.1 (2.6–3.5) 3.4 (2.9–4.4)
SVRI (dyne.s.cm5/m2), median (P25-P75) 2599 (2212–3083) 2797 (2477–3185) 2472 (2142–2922)
VI (1/1000/s), median (P25-P75) 39 (31–48) 36 (29–44) 40 (31–49)
AHT antihypertensive, CI cardiac index, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, DBP diastolic blood pressure, HR heart rate, LCWI
left cardiac work index, LVDD left ventricle diastolic dysfunction, MBP mean blood pressure, OSA obstructive sleep apnoea, SBP systolic blood pressure, SVI stroke
volume index, SVRI systemic vascular resistance index, VI Aorta velocity index
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LVDD screening: PEP ≤ 104 ms, LVET ≥ 320 ms;
STR ≤ 0.31. Table 4 presents the results of the LVDD
diagnostic evaluation with the ICG variables PEP,
LVET, STR and D wave.
The misclassification of LVDD using STR affected 6
cases, one false negative (FN) and five false positive (FP).
The only FN case had STR = 0.32, which is only slightly
above the cut-off value 0.31. No demographic, clinical and
hemodynamic characteristics were found that differenti-
ated the misclassified cases from the rest of the sample.
Discussion
In the IMPEDDANS study, the STR, with sensitivity
of 99.0% and specificity of 90.9%, outperformed the
other analysed variables as screening test for LVDD.
This index only misclassified 5 FP cases, which deter-
mine a 95.3% PPV, and 1 FN case, which determines
a 98.0% NPV.
In the IMPEDDANS study, PEP ≤ 104 ms was identi-
fied as a good screening test for LVDD with sensitivity
of 90.2% and PPV of 79.3%. PEP extends from the onset












































ICG impedance cardiography, LVDD left ventricular diastolic dysfunction, LVET left ventricle ejection time, PEP pre-ejection period, STR systolic time ratio, TFC thoracic
fluid content
Fig. 3 Distribution of the values of (a) pre-ejection period (PEP), b left ventricle ejection time (LVET), c systolic time ratio (STR) and d thoracic fluid
content (TFC), as assessed by ICG, according with the diagnosis of LVDD (left ventricular diastolic dysfunction) by echocardiography. Graphics
represent the interquartile range (P25-P75), median, limits and outliers. Comparison by Mann-Whitney test
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of ventricular depolarization to the opening of the aortic
valve. It is composed of two sub-intervals, known as the
period of the electromechanical coupling and the period
of elevation of pressure (or isovolumetric systole). The
electromechanical coupling period undergoes few
changes in acute interventions, but changes in the final
diastolic pressure, aortic diastolic pressure and in the
mean velocity of elevation of LV pressure (usually
predominantly) in this period are the factors that deter-
mine the period of pressure rise and, consequently, PEP.
Elevation of LV end-diastolic pressure (LVEDP),
reduction of aortic diastolic pressure or gain in the rate
of pressure increase in the pre-ejection period, lead to a
time reduction. In mild LVDD, we expect a rise in
LVEDP and a shortening of PEP, as we confirmed in this
sample [16–18]. However, we must point out that
LVEDP, aortic diastolic pressure or alterations in the rate
of pressure increase can act simultaneously and we can
have an unexpected PEP time. For example, in the estab-
lished heart failure, the final diastolic pressure is in-
creased, but the rate of ventricular pressure elevation in
the pre-ejective period is so slow that it predominates
Fig. 4 Discriminative ability of PEP, LVET, STR and D wave to identify LVDD in hypertensive patients, as determined by the AUC and ROC curves.
STR AUC = 0.97; PEP AUC = 0.81; LVET AUC = 0.82; D Wave AUC = 0.88. AUC, area under the curve; LVDD, left ventricular diastolic dysfunction;
LVET, left ventricle ejection time; PEP, pre-ejection period; STR, systolic time ratio
Table 4 Diagnostic performance of ICG-derived indexes for identification of LVDD, for the identified cut-off points (n = 157)














































FN false negative diagnostics, FP false positive diagnostics, NPV negative predictive value, LVDD left ventricular diastolic dysfunction, LVET left ventricle ejection
time, PEP pre-ejection period, PPV positive predictive value, STR systolic time ratio, TN true negative diagnostics, TP true positive diagnostics
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and prolongs PEP. In this sample, it was not the case,
because we excluded the patients with heart failure [16–
18].
Increased LVET (≥ 320 ms) was also a good LVDD
screening tool with sensitivity 90.2%, and PPV 76.6%. Con-
sidering that active relaxation can be considered in the
strictest sense as an early diastolic event, the time of onset
of this process depends, at least in part, on systolic events
such as the duration of contraction. In LVDD, increases in
load during the contraction phase induce compensatory in-
creases in duration of systole (LVET) and delayed onset of
relaxation, which explain these results [27, 28].
The diastolic properties of the LV are largely determined
by the size or volume of the LV, the thickness, physical
properties of the ventricular wall and the relaxation process
of the myocardium. Thus, a combination of increased myo-
cardial mass and changes in the extracellular collagen net-
work may cause or contribute to an increase in the passive
elastic rigidity of the ventricle with a diastolic pressure-
volume relation represented by a steep curve. Disorders of
the active myocardial relaxation process, acting alone or in
conjugation with abnormal passive ventricular properties,
may also cause increased ventricular rigidity. As a result,
there is a reduction in the compliance and distensibility of
the ventricle, the filling dynamics are changed and the final
diastolic pressure increases. Under these circumstances, as
the disease progresses, an increase in central blood volume
may produce a substantial increase in LV diastolic pressure
and, consequently, cause some degree of pulmonary
congestion, which can be evidenced by an increase in TFC
[13, 29, 30]. In the IMPEDDANS study, however, we did
not verify any relation between LVDD and TFC. We
hypothesize that this is related with the important
proportion of resistant hypertensive patients which are
polymedicated (n = 117, 74.5% of the total sample; 48.4% of
the patients with LVDD, n = 76), most of them taking di-
uretics (n = 82, 80.4%). On the other hand, pulmonary con-
gestion is more common in an advanced phase of
hypertensive disease, when patients start to evidence heart
failure symptoms, which were not included (only patients
with mild asymptomatic LVDD were included).
During early diastole, the occurrence of a prominent
wave may indicate diastolic dysfunction. As such, the
presence of a pronounced diastolic O wave (D wave), in
either upright or supine position, can be assumed as an
evidence of diastolic dysfunction [2]. Thus, it was verified
that the presence of a D wave was statistically related with
LVDD and that it had good performance screening LVDD,
with 79.4% of sensitivity and 97.6% PPV.
Our observational study has some weak points: the two
tests were performed within a time lapse of 8 days. In
order to minimize this weakness, evaluations matching
variations >10% in BP or variations >5% in HR were not
considered. Although sample was recruited by conveni-
ence of researchers all patients had strict inclusion and ex-
clusion criteria, were submitted to the same evaluation
protocols and patients were recruited non-consecutively.
Significant strengths are the exclusion of the elderly (due
to the influence of age on the physiopathology of diastolic
dysfunction), and the fact that examinations have been
performed in a clinical environment controlled by experi-
enced professionals under well-defined protocols.
Recommendations for the diagnosis of diastolic dys-
function were updated in 2016 (Fig. 5 presents the diag-
nostic approach proposed) [31]. However, there is no
real consensus in the scientific community regarding its
Fig. 5 Practical approach to diagnose diastolic dysfunction (adapted from Nagueh et al. [31])
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applicability due to the fact that they have not yet been
duly validated and just during this year was presented
the first trial studying their applicability being difficult to
conclude about their performance [32, 33]. We can,
however, admit that the new recommendations create
situations in which diastolic dysfunction may be under-
diagnosed. In fact, the inclusion of the tricuspid regurgi-
tation peak velocity as a criterion for the diagnosis and
classification of diastolic dysfunction may lead to some
interpretation problems because high values may be due
to pulmonary hypertension and its increase is usually as-
sociated with elevation of pulmonary artery pressure due
to increased filling pressures of the left ventricle, phe-
nomena present in advanced stages of diastolic dysfunc-
tion [34–37]. Thus, we can only diagnose diastolic
dysfunction in patients with established heart failure and
patients with diastolic dysfunction at an early stage may
go unnoticed, which goes against the spirit of this study,
whose aim is to diagnose patients at an early stage,
asymptomatic, without heart failure. In addition, the
adoption of new recommendations would bring the limi-
tation of not allow to compare our results with previous
studies and perform other substudies with the acquired
data. After analyzing these points and considering that
these recommendations were published in the middle of
the study period, we chose to not integrate them into
our protocol and to keep the previous recommenda-
tions, already studied and validated.
Despite all the potential demonstrated by the ICG, we
must emphasize the importance of performing routine
echocardiography in hypertensive patients, indispensable
to provide the recommended basic echocardiographic as-
sessments [4]. In hypertensive patients ICG can be a valid,
cost effective alternative for LVDD screening, it might also
be used to monitor follow-up and define patients who
would benefit from early transthoracic echocardiography.
Conclusions
ICG can accurately screen LVDD in hypertensive pa-
tients, using its derived parameters STR, PEP, LVET
and D wave. STR alone showed the highest discrim-
inative ability. Therefore, we recommend its use as a
LVDD screening tool.
Future ICG studies applying the diagnostic test for LVDD
will probably increase our understanding of the physiopa-
thology/hemodynamics of HT and demonstrate that earlier
detection and treatment of these hemodynamic features
will favour patients’ evolution and, perhaps, reduce morbid-
ity and mortality.
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index; TN: True negatives; TP: True positives; VEPT: Volume of electrically
participating tissue; VI: Aorta velocity index; VSR: Vascular systemic resistence;
VSRI: Vascular systemic resistance index
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